Laboratory diagnostics of inherited platelet disorders

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 8, 2014, Pages 1091-1106

  Carubbi, Cecilia ^a   Masselli, Elena ^a   Nouvenne, Antonio ^a   Russo, Domenico ^b   Galli, Daniela ^a   Mirandola, Prisco ^a   Gobbi, Giuliana ^a   Vitale, Marco ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

Author keywords

bleeding; laboratory tests; platelets; rare diseases

Indexed keywords

ACUTE LEUKEMIA; ALGORITHM; BENIGN MEDITERRANEAN MACROTHROMBOCYTOPENIA; CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA; DIFFERENTIAL DIAGNOSIS; DYSERYTHROPOIESIS; FAMILIAL DISEASE; FAMILIAL THROMBOCYTOPENIA 2; GENETIC DISORDER; GLANZMANN DISEASE; GRAY PLATELET SYNDROME; HUMAN; INHERITED PLATELET DISORDER; LABORATORY TEST; MAY HEGGLIN ANOMALY; PLATELET TYPE VON WILLEBRAND DISEASE; PRIORITY JOURNAL; REVIEW; SCOTT SYNDROME; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; THROMBOCYTE DYSFUNCTION; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE; WISKOTT ALDRICH SYNDROME; LABORATORY; PATHOLOGY; STANDARDS; THROMBOCYTE;

BLOOD PLATELET DISORDERS; BLOOD PLATELETS; HUMANS; LABORATORIES;

EID: 84903976193     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0131     Document Type: Review

References (103)

1. Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006;135:603-33.
2. Diz-Kucukkaya R. Inherited platelet disorders including Glanzmann thrombasthenia and Bernard-Soulier syndrome. Hematology Am Soc Hematol Educ Program 2013;2013:268-75.
3. Lambert MP. What to do when you suspect an inherited platelet disorder. Hematology Am Soc Hematol Educ Program 2011;2011:377-83.
4. Franchini M, Lippi G, Veneri D, Targher G, Zaffanello M, Guidi GC. Inherited platelet disorders. Clin Chim Acta 2008;387:1-8.
5. Lambert MP, Poncz M. Inherited thrombocytopenias. In: Michelson AD, editor. Platelets, 3rd ed. Amsterdam: Academic Press, 2013:971-87.
6. Balduini CL, Cattaneo M, Fabris F, Gresele P, Iolascon A, Pulcinelli FM, et al. Inherited thrombocytopenias: a proposed diagnostic algorithm from the Italian Gruppo di Studio delle Piastrine. Haematologica 2003;88:582-92.
7. Seri M, Cusano R, Gangarossa S, Caridi G, Bordo D, Lo Nigro C, et al. Mutations in MYH9 result in the May-Hegglin anomaly, and Fechtner and Sebastian syndromes. The May-Heggllin/Fechtner Syndrome Consortium. Nat Genet 2000;26:103-5.
8. Heath KE, Campos-Barros A, Toren A, Rozenfeld-Granot G, Carlsson LE, Savige J, et al. Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes. Am J Hum Genet 2001;69:1033-45.
9. Balduini CL, Pecci A, Savoia A. Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias. Br J Haematol 2011;154:161-74.
10. Geddis AE. Congenital amegakaryocytic thrombocytopenia. Pediatr Blood Cancer 2011;57:199-203.
11. Ballmaier M, Germeshausen M, Schulze H, Cherkaoui K, Lang S, Gaudig A, et al. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood 2001;97:139-46.
12. Letestu R, Vitrat N, Masse A, Le Couedic JP, Lazar V, Rameau P, et al. Existence of a differentiation blockage at the stage of a megakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome. Blood 2000;95:1633-41.
13. Thompson AA, Woodruff K, Feig SA, Nguyen LT, Schanen NC. Congenital thrombocytopenia and radio-ulnar synostosis: a new familial syndrome. Br J Haematol 2001;113:866-70.
14. Thompson AA, Nguyen LT. Amegakaryocytic thrombocytopenia and radio-ulnar synostosis are associated with HOXA11 mutation. Nat Genet 2000;26:397-8.
15. Van Geet C, Devriendt K, Eyskens B, Vermylen J, Hoylaerts MF. Velocardiofacial syndrome patients with a heterozygous chromosome 22q11 deletion have giant platelets. Pediatr Res 1998;44:607-11.
16. Yu C, Niakan KK, Matsushita M, Stamatoyannopoulos G, Orkin SH, Raskind WH. X-linked thrombocytopenia with thalassemia from a mutation in the amino finger of GATA-1 affecting DNA binding rather than FOG-1 interaction. Blood 2002;100:2040-5.
17. Owen CJ, Toze CL, Koochin A, Forrest DL, Smith CA, Stevens JM, et al. Five new pedigrees with inherited RUNX1 mutations' causing familial platelet disorder with propensity to myeloid malignancy. Blood 2008;112:4639-45.
18. Dowton SB, Beardsley D, Jamison D, Blattner S, Li FP. Studies of a familial platelet disorder. Blood 1985;65:557-63.
19. Owen C. Insights into familial platelet disorder with propensity to myeloid malignancy (FPD/AML). Leuk Res 2010;34:141-2.
20. Behrens WE. Mediterranean macrothrombocytopenia. Blood 1975;46:199-208.
21. Engler J, Thiemann KH. Are the current efforts for habilitation and rehabilitation of patients with muscular dystrophy adequate? Demonstrated on follow-up examinations of former patients of the Orthopedic Clinical Center Birkenwerder. Beitr Orthop Traumatol 1975;22:43-5.
22. Savoia A, Del Vecchio M, Totaro A, Perrotta S, Amendola G, Moretti A, et al. An autosomal dominant thrombocytopenia gene maps to chromosomal region 10p. Am J Hum Genet 1999;65:1401-5.
23. Gandhi MJ, Cummings CL, Drachman JG. FLJ14813 missense mutation: a candidate for autosomal dominant thrombocytopenia on human chromosome 10. Hum Hered 2003;55:66-70.
24. Punzo F, Mientjes EJ, Rohe CF, Scianguetta S, Amendola G, Oostra BA, et al. A mutation in the acyl-coenzyme A binding domain-containing protein 5 gene (ACBD5) identified in autosomal dominant thrombocytopenia. J Thromb Haemost 2010;8:2085-7.
25. Pippucci T, Savoia A, Perrotta S, Pujol-Moix N, Noris P, Castegnaro G, et al. Mutations in the 5 UTR of ANKRD26, the ankirin repeat domain 26 gene, cause an autosomal-dominant form of inherited thrombocytopenia, THC2. Am J Hum Genet 2011;88:115-20.
26. Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, et al. Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011;155:30-44.
27. Favaloro EJ, Lippi G, Franchini M. Contemporary platelet function testing. Clin Chem Lab Med 2010;48:579-98.
28. Carubbi C, Masselli E, Gesi M, Galli D, Mirandola P, Vitale M, et al. Cytofluorimetric platelet analysis. Semin Thromb Hemost 2014;40:88-98.
29. Hayward CP, Moffat KA, Liu Y. Laboratory investigations for bleeding disorders. Semin Thromb Hemost 2012;38:742-52.
30. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009;35:158-67.
31. Rand ML, Leung R, Packham MA. Platelet function assays. Transfus Apher Sci 2003;28:307-17.
32. Gobbi G, Sponzilli I, Mirandola P, Tazzari PL, Caimi L, Cacchioli A, et al. Efficient platelet delta-granule release induced by [Ca2+]i elevation is modulated by GPIIbIIIa. Int J Mol Med 2006; 18:309-13.
33. Michelson AD. Evaluation of platelet function by flow cytometry. Pathophysiol Haemost Thromb 2006;35:67-82.
34. Gobbi G, Mirandola P, Tazzari PL, Ricci F, Caimi L, Cacchioli A, et al. Flow cytometry detection of serotonin content and release in resting and activated platelets. Br J Haematol 2003;121:892-6.
35. Michelson AD, Barnard MR, Hechtman HB, MacGregor H, Connolly RJ, Loscalzo J, et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996;93:11877-82.
36. Clauser S, Cramer-Borde E. Role of platelet electron microscopy in the diagnosis of platelet disorders. Semin Thromb Hemost 2009;35:213-23.
37. Kronick PL, Jimenez SA. Simultaneous aggregation and release from platelets monitored continuously in plasma. Thromb Res 1976;9:553-63.
38. Greenberg J, Packham MA, Cazenave JP, Reimers HJ, Mustard JF. Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest 1975;32:476-84.
39. Kaplan KL, Owen J. Plasma levels of beta-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo. Blood 1981;57:199-202.
40. Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC hemostasis study-I. Development of a blood collection and processing system suitable for multicenter hemostatic studies. Thromb Haemost 1989;61:15-9.
41. Pham A, Wang J. Bernard-Soulier syndrome: an inherited platelet disorder. Arch Pathol Lab Med 2007;131:1834-6.
42. Mitsui T, Yokoyama S, Yazaki N, Hayashi T, Suzuki K, Shimizu Y, et al. Severe bleeding tendency in a patient with Bernard-Soulier syndrome associated with a homozygous single base pair deletion in the gene coding for the human platelet glycoprotein Ibalpha. J Pediatr Hematol Oncol 1998;20:246-51.
43. Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 1998;91:4397-418.
44. Balduini CL, Iolascon A, Savoia A. Inherited thrombocytopenias: from genes to therapy. Haematologica 2002;87:860-80.
45. Franchini M. The platelet-function analyzer (PFA-100) for evaluating primary hemostasis. Hematology 2005;10:177-81.
46. Geddis AE, Kaushansky K. Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production. Curr Opin Pediatr 2004;16:15-22.
47. Noris P, Spedini P, Belletti S, Magrini U, Balduini CL. Thrombocytopenia, giant platelets, and leukocyte inclusion bodies (May-Hegglin anomaly): clinical and laboratory findings. Am J Med 1998;104:355-60.
48. Nurden AT, Phillips DR, George JN. Platelet membrane glycoproteins: historical perspectives. J Thromb Haemost 2006;4:3-9.
49. Bennet JS. Hereditary disorders of platelet function. Hematology: basic principles and practice. 5th ed. Philadelphia, PA: Churchill Livingstone, 2009:2133-43.
50. Bellucci S, Caen J. Molecular basis of Glanzmann's Thrombasthenia and current strategies in treatment. Blood Rev 2002;16:193-202.
51. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990;75:1383-95.
52. Franchini M, Favaloro EJ, Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta 2010;411:1-6.
53. Lobo V, Shetty S, Kulkarni B, Ghosh K. A novel ELISA for diagnosis of Glanzmann's thrombasthenia and the heterozygote carriers. Ann Hematol 2012;91:917-21.
54. Othman M. Platelet-type von Willebrand disease: a rare, often misdiagnosed and underdiagnosed bleeding disorder. Semin Thromb Hemost 2011;37:464-9.
55. Franchini M, Montagnana M, Lippi G. Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease. Int J Lab Hematol 2008;30:91-4.
56. Miller JL. Platelet-type von Willebrand disease. Thromb Haemost 1996;75:865-9.
57. Othman M, Kaur H, Emsley J. Platelet-type von Willebrand disease: new insights into the molecular pathophysiology of a unique platelet defect. Sem Thromb Haemost 2013;33:663-73.
58. Giannini S, Cecchetti L, Mezzasoma AM, Gresele P. Diagnosis of platelet-type von Willebrand disease by flow cytometry. Haematologica 2010;95:1021-4.
59. Notarangelo LD, Miao CH, Ochs HD. Wiskott-Aldrich syndrome. Curr Opin Hematol 2008;15:30-6.
60. Villa A, Notarangelo L, Macchi P, Mantuano E, Cavagni G, Brugnoni D, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet 1995;9:414-7.
61. Kenney DM, Reid R, Parent DW, Rosen FS, Remold-O'Donnell E. Evidence implicating calpain (Ca(2+)-dependent neutral protease) in the destructive thrombocytopenia of the Wiskott-Aldrich syndrome. Br J Haematol 1994;87:773-81.
62. Rengan R, Ochs HD, Sweet LI, Keil ML, Gunning WT, Lachant NA, et al. Actin cytoskeletal function is spared, but apoptosis is increased, in WAS patient hematopoietic cells. Blood 2000;95:1283-92.
63. Sandrock K, Zieger B. Current strategies in diagnosis of inherited storage pool defects. Transfus Med Hemother 2010;37:248-58.
64. Ward DM, Shiflett SL, Kaplan J. Chediak-Higashi syndrome: a clinical and molecular view of a rare lysosomal storage disorder. Curr Mol Med 2002;2:469-77.
65. Huizing M, Anikster Y, Gahl WA. Hermansky-Pudlak syndrome and Chediak-Higashi syndrome: disorders of vesicle formation and trafficking. Thromb Haemost 2001;86:233-45.
66. Spritz RA. Multi-organellar disorders of pigmentation: tied up in traffic. Clin Genet 1999;55:309-17.
67. Huizing M, Helip-Wooley A, Westbroek W, Gunay-Aygun M, Gahl WA. Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics. Annu Rev Genomics Hum Genet 2008;9:359-86.
68. Garay SM, Gardella JE, Fazzini EP, Goldring RM. Hermansky-Pudlak syndrome. Pulmonary manifestations of a ceroid storage disorder. Am J Med 1979;66:737-47.
69. Morgan NV, Pasha S, Johnson CA, Ainsworth JR, Eady RA, Dawood B, et al. A germline mutation in BLOC1S3/reduced pigmentation causes a novel variant of Hermansky-Pudlak syndrome (HPS8). Am J Hum Genet 2006;78:160-6.
70. Nurden AT, Nurden P. The gray platelet syndrome: clinical spectrum of the disease. Blood Rev 2007;21:21-36.
71. Nurden AT, Kunicki TJ, Dupuis D, Soria C, Caen JP. Specific protein and glycoprotein deficiencies in platelets isolated from two patients with the gray platelet syndrome. Blood 1982;59:709-18.
72. Rosa JP, George JN, Bainton DF, Nurden AT, Caen JP, McEver RP. Gray platelet syndrome. Demonstration of alpha granule membranes that can fuse with the cell surface. J Clin Invest 1987;80:1138-46.
73. Cramer EM, Savidge GF, Vainchenker W, Berndt MC, Pidard D, Caen JP, et al. Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes. Blood 1990;75:1220-7.
74. Breton-Gorius J, Vainchenker W, Nurden A, Levy-Toledano S, Caen J. Defective alpha-granule production in megakaryocytes from gray platelet syndrome: ultrastructural studies of bone marrow cells and megakaryocytes growing in culture from blood precursors. Am J Pathol 1981;102:10-9.
75. Gebrane-Younes J, Cramer EM, Orcel L, Caen JP. Gray platelet syndrome. Dissociation between abnormal sorting in megakaryocyte alpha-granules and normal sorting in Weibel-Palade bodies of endothelial cells. J Clin Invest 1993;92:3023-8.
76. Jantunen E, Hanninen A, Naukkarinen A, Vornanen M, Lahtinen R. Gray platelet syndrome with splenomegaly and signs of extramedullary hematopoiesis: a case report with review of the literature. Am J Hematol 1994;46:218-24.
77. Gunay-Aygun M, Zivony-Elboum Y, Gumruk F, Geiger D, Cetin M, Khayat M, et al. Gray platelet syndrome: natural history of a large patient cohort and locus assignment to chromosome 3p. Blood 2010;116:4990-5001.
78. Hayward CP. Inherited disorders of platelet alpha-granules. Platelets 1997;8:197-209.
79. Grossfeld PD, Mattina T, Lai Z, Favier R, Jones KL, Cotter F, et al. The 11q terminal deletion disorder: a prospective study of 110 cases. Am J Med Genet A 2004;129A:51-61.
80. Blavignac J, Bunimov N, Rivard GE, Hayward CP. Quebec platelet disorder: update on pathogenesis, diagnosis, and treatment. Semin Thromb Hemost 2011;37:713-20.
81. Hayward CP, Cramer EM, Kane WH, Zheng S, Bouchard M, Masse JM, et al. Studies of a second family with the Quebec platelet disorder: evidence that the degradation of the alphagranule membrane and its soluble contents are not secondary to a defect in targeting proteins to alpha-granules. Blood 1997;89:1243-53.
82. Hayward CP, Rivard GE, Kane WH, Drouin J, Zheng S, Moore JC, et al. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood 1996;87: 4967-78.
83. Paterson AD, Rommens JM, Bharaj B, Blavignac J, Wong I, Diamandis M, et al. Persons with Quebec platelet disorder have a tandem duplication of PLAU, the urokinase plasminogen activator gene. Blood 2010;115:1264-6.
84. Zwaal RF, Comfurius P, Bevers EM. Scott syndrome, a bleeding disorder caused by defective scrambling of membrane phospholipids. Biochim Biophys Acta 2004;1636:119-28.
85. Satta N, Toti F, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome: an inherited defect of the procoagulant activity of platelets. Platelets 1997;8:117-24.
86. Lhermusier T, Chap H, Payrastre B. Platelet membrane phospholipid asymmetry: from the characterization of a scramblase activity to the identification of an essential protein mutated in Scott syndrome. J Thromb Haemost 2011;9: 1883-91.
87. Rosing J, Bevers EM, Comfurius P, Hemker HC, van Dieijen G, Weiss HJ, et al. Impaired factor X and prothrombin activation associated with decreased phospholipid exposure in platelets from a patient with a bleeding disorder. Blood 1985;65: 1557-61.
88. Toti F, Satta N, Fressinaud E, Meyer D, Freyssinet JM. Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood 1996;87:1409-15.
89. Albrecht C, McVey JH, Elliott JI, Sardini A, Kasza I, Mumford AD, et al. A novel missense mutation in ABCA1 results in altered protein trafficking and reduced phosphatidylserine translocation in a patient with Scott syndrome. Blood 2005;106:542-9.
90. Cattaneo M. The platelet P2Y(1)(2) receptor for adenosine diphosphate: congenital and drug-induced defects. Blood 2011;117:2102-12.
91. Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992;80:2787-96.
92. Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest 1995;95:1612-22.
93. Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet 'primary secretion defect' are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 2000;20:E101-6.
94. Shiraga M, Miyata S, Kato H, Kashiwagi H, Honda S, Kurata Y, et al. Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon. J Thromb Haemost 2005;3:2315-23.
95. Cattaneo M, Zighetti ML, Lombardi R, Martinez C, Lecchi A, Conley PB, et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci USA 2003;100: 1978-83.
96. Remijn JA, IJsseldijkMJ, Strunk AL, Abbes AP, Engel H, Dikkeschei B, et al. Novel molecular defect in the platelet ADP receptor P2Y12 of a patient with haemorrhagic diathesis. Clin Chem Lab Med 2007;45:187-9.
97. Daly ME, Dawood BB, Lester WA, Peake IR, Rodeghiero F, Goodeve AC, et al. Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood 2009;113:4110-3.
98. Higuchi W, Fuse I, Hattori A, Aizawa Y. Mutations of the platelet thromboxane A2 (TXA2) receptor in patients characterized by the absence of TXA2-induced platelet aggregation despite normal TXA2 binding activity. Thromb Haemost 1999;82:1528-31.
99. Mitsui T, Yokoyama S, Shimizu Y, Katsuura M, Akiba K, Hayasaka K. Defective signal transduction through the thromboxane A2 receptor in a patient with a mild bleeding disorder: deficiency of the inositol 1,4,5-triphosphate formation despite normal G-protein activation. Thromb Haemost 1997;77:991-5.
100. Fuse I, Hattori A, Mito M, Higuchi W, Yahata K, Shibata A, et al. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thromboxane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity. Thromb Haemost 1996;76:1080-5.
101. Zighetti ML, Carpani G, Sinigaglia E, Cattaneo M. Usefulness of a flow cytometric analysis of intraplatelet vasodilatorstimulated phosphoprotein phosphorylation for the detection of patients with genetic defects of the platelet P2Y(12) receptor for ADP. J Thromb Haemost 2010;8:2332-4.
102. Ushikubi F, Okuma M, Kanaji K, Sugiyama T, Ogorochi T, Narumiya S, et al. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity. Thromb Haemost 1987;57:158-64.
103. Balduini CL, Pecci A, Noris P. Diagnosis and management of inherited thrombocytopenias. Semin Thromb Hemost 2013;39:161-71.